Full View

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges

R Uraki, M Kiso, K Iwatsuki-Horimoto… - Journal of …, 2013 - journals.asm.org
Vaccination is an effective means to protect against influenza virus. Although inactivated and
live-attenuated vaccines are currently available, each vaccine has disadvantages (eg …
Save Cite Cited by 52 Related articles Full View

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges

R Uraki, M Kiso, K Iwatsuki-Horimoto, S Fukuyama… - Journal of …, 2013 - hero.epa.gov
Vaccination is an effective means to protect against influenza virus. Although inactivated and
live-attenuated vaccines are currently available, each vaccine has disadvantages (eg …
Cite

A Novel Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice from Pandemic H1N1 and Highly Pathogenic H5N1 Virus Challenges

R Uraki, M Kiso, K Iwatsuki-Horimoto, S Fukuyama… - Journal of …, 2013 - cir.nii.ac.jp
抄録< jats: title> ABSTRACT</jats: title>< jats: p> Vaccination is an effective means to protect
against influenza virus. Although inactivated and live-attenuated vaccines are currently …
Cite
[PDF] researchgate.net

[PDF][PDF] A Novel Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice from Pandemic H1N1 and Highly Pathogenic H5N1 Virus Challenges

R Uraki, M Kiso, K Iwatsuki-Horimoto, S Fukuyama… - 2013 - researchgate.net
MATERIALS AND METHODS Cells and viruses. Human embryonic kidney HEK293T cells (a
derivative of the HEK293 line into which the gene for simian virus 40 T antigen was inserted …
Cite
[HTML] nih.gov

[HTML][HTML] A Novel Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice from Pandemic H1N1 and Highly Pathogenic H5N1 Virus Challenges

R Uraki, M Kiso, K Iwatsuki-Horimoto… - Journal of …, 2013 - pmc.ncbi.nlm.nih.gov
Vaccination is an effective means to protect against influenza virus. Although inactivated and
live-attenuated vaccines are currently available, each vaccine has disadvantages (eg …
Cite

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

R Uraki, M Kiso, K Iwatsuki-Horimoto… - Journal of …, 2013 - europepmc.org
Vaccination is an effective means to protect against influenza virus. Although inactivated and
live-attenuated vaccines are currently available, each vaccine has disadvantages (eg …
Cite

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges

R Uraki, M Kiso, K Iwatsuki-Horimoto… - Journal of …, 2013 - pubmed.ncbi.nlm.nih.gov
Vaccination is an effective means to protect against influenza virus. Although inactivated and
live-attenuated vaccines are currently available, each vaccine has disadvantages (eg …
Cite

A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

R Uraki, M Kiso, K Iwatsuki-Horimoto… - Journal of …, 2013 - europepmc.org
Vaccination is an effective means to protect against influenza virus. Although inactivated and
live-attenuated vaccines are currently available, each vaccine has disadvantages (eg …
Cite